Moderna: Sell The Cancer Vaccine Hype

What happened: A Seeking Alpha analyst rates Moderna a Sell, arguing the stock price exceeds even the most bullish fair value estimates and depends on intismeran matching Keytruda-scale success. Key numbers: Valuation implies $69B in peak intismeran sales, though Moderna owns only half; first approval is unlikely before 2027; probability-weighted models support a value closer to $110 Why it matters: The analyst says the market is pricing in a perfect outcome while the pivotal Phase 3 hazard ratio and broader oncology data remain undisclosed, and the vaccine business continues to burn cash.

A Seeking Alpha analyst rates Moderna a Sell, arguing the stock price exceeds even the most bullish fair value estimates and depends on intismeran matching Keytruda-scale success.

The analyst says the market is pricing in a perfect outcome while the pivotal Phase 3 hazard ratio and broader oncology data remain undisclosed, and the vaccine business continues to burn cash.